CAI News & Events

Reports Q1 revenue $216.2M, consensus $209.67M. "We delivered another strong quarter with record performance for February and March following our January sales re-alignment. This performance underscores the continued demand for our platform and the strength of our comprehensive, patient-first approach," said CEO David Dean Halbert. "We are also encouraged by the Achieve 1 data, including the blinded readout, which demonstrates the superior performance of our whole genome technology over inferior techniques such as methylation. We remain focused on strengthening Caris Detect through the incorporation of additional pillars in advance of our upcoming launch."

Caris Life Sciences still sees 2026 revenue $1.0B-$1.02B, consensus $1.01B

Caris Life Sciences announced that Caris ChromoSeq has received MolDX approval, a milestone supporting broader clinical access to Caris' comprehensive whole genome tumor profiling assay for myeloid malignancies. The Molecular Diagnostic Services, or MolDX, program, administered by Palmetto GBA on behalf of the Centers for Medicare & Medicaid Services or CMS, evaluates molecular diagnostic tests to determine whether they demonstrate clinical validity and utility to support coverage and reimbursement decisions. MolDX approval reflects a rigorous review of the test performance and medical usefulness. Caris ChromoSeq is the first and only ultra-deep whole genome sequencing, or WGS, assay for myeloid malignancies. Caris ChromoSeq is designed to support the comprehensive clinical genomic evaluation of acute myeloid leukemia or AML, myelodysplastic syndromes or MDS, myeloproliferative neoplasms or MPN, and other suspected myeloid malignancies. Caris ChromoSeq is designed to replace serial testing with one integrated approach. Results are consolidated into a single clinical report to support timely treatment decisions.